Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Psychopharmacol ; 37(6): 577-589, 2023 06.
Article in English | MEDLINE | ID: mdl-37165642

ABSTRACT

BACKGROUND: Up to 40% of patients suffering from anxiety disorders do not benefit from currently available pharmacological treatments. Overactivity of the orexin-1 receptor (OX1R) has been implicated in anxiety- and panic-related states. AIM & METHODS: We investigated the pharmacokinetics and characterized the pharmacodynamic (PD) profile of the OX1R antagonist JNJ-61393215 using a battery of central nervous system assessments investigating relevant functional domains such as alertness, attention, (visuo)motor coordination, balance, subjective effects and resting-state electroencephalography in a single ascending dose placebo-controlled study in doses from 1 to 90 mg inclusive, assessing PD up to 10 h after dosing, safety and pharmacokinetic in 48 healthy male subjects. RESULTS: Average time to maximal plasma concentration (Tmax) ranged between 1.0 and 2.25 h; average half-life ranged from 13.6 to 24.6 h and average maximum plasma concentration ranged from 1.4 to 136.8 ng/mL in the 1 and 90 mg groups, respectively. JNJ-61393215 did not demonstrate any statistically significant or clinically meaningful effects on any PD endpoint at any dose investigated at Tmax nor over the total period up to 10 h post-dose and was well tolerated. The reported somnolence rate was 16.7% (which was attributable to the cohorts receiving 6 mg and higher doses) compared to 12.5% in placebo. CONCLUSION: This observation is in line with our knowledge about the OX1R in preclinical studies, where only inconsistent and non-dose-dependent changes in electroencephalography or other behavioural measures were observed under non-challenged conditions, potentially exemplifying the need for a challenged subject.


Subject(s)
Orexin Receptor Antagonists , Humans , Male , Area Under Curve , Dose-Response Relationship, Drug , Double-Blind Method , Half-Life , Healthy Volunteers , Orexin Receptor Antagonists/adverse effects , Orexin Receptor Antagonists/pharmacokinetics , Orexins
2.
Aust Dent J ; 42(4): 228-32, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9316309

ABSTRACT

Orofacial granulomatosis is a condition that may be difficult to diagnose for those unfamiliar with the entity. This paper describes two cases and addresses the presentation, pathogenesis and treatment. The clinical recognition of this condition is important as is the subsequent investigation by an appropriate specialist. Management of patients needs to take into account the results of further investigations, the patient's expectations, and the severity of the condition.


Subject(s)
Face , Granuloma/diagnosis , Mouth Diseases/diagnosis , Anti-Inflammatory Agents/therapeutic use , Cheilitis/pathology , Child , Chronic Disease , Diagnosis, Differential , Female , Giant Cells/pathology , Gingival Hypertrophy/pathology , Granuloma/etiology , Granuloma/pathology , Granuloma/therapy , Humans , Lip Diseases/pathology , Male , Mouth Diseases/etiology , Mouth Diseases/pathology , Mouth Diseases/therapy , Mouth Mucosa/pathology , Sulfasalazine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...